Abstract:Metabolic reprogramming and altered cellular energetics have been recently established as an important cancer hallmark. The modulation of glucose metabolism is one of the important characteristic features of metabolic reprogramming in cancer. It contributes to oncogenic progression by supporting the increased biosynthetic and bio-energetic demands of tumor cells. This oncogenic transformation consequently results in elevated expression of glucose transporters in these cells. Moreover, various cancers exhibit abnormal transporter expression patterns compared to normal tissues. Recent investigations have underlined the significance of glucose transporters in regulating cancer cell survival, proliferation, and metastasis. Abnormal regulation of these transporters, which exhibit varying affinities for hexoses, could enable cancer cells to efficiently manage their energy supply, offering a crucial edge for proliferation. Exploiting the upregulated expression of glucose transporters, GLUTs, and Sodium Linked Glucose Transporters (SGLTs), could serve as a novel therapeutic intervention for anti-cancer drug discovery as well as provide a unique targeting approach for drug delivery to specific tumor tissues. This review aims to discussthe previous and emerging research on the expression of various types of glucose transporters in tumor tissues, the role of glucose transport inhibitors as a cancer therapy intervention as well as emerging GLUT/SGLT-mediated drug delivery strategies that can be therapeutically employed to target various cancers.

Glucose Transporter-Targeting Chimeras Enabling Tumor-Selective Degradation of Secreted and Membrane Proteins

Lysosome Targeting Chimaeras for Glut1-Facilitated Targeted Protein Degradation

Development of folate receptor targeting chimeras for cancer selective degradation of extracellular proteins

Targeted Protein Degradation Mediated by Genetically Engineered Lysosome-Targeting Exosomes

GLUT1 targeting and hypoxia-activating polymer-drug conjugate-based micelle for tumor chemo-thermal therapy

Envisioning Glucose Transporters (GLUTs and SGLTs) as Novel Intervention against Cancer: Drug Discovery Perspective and Targeting Approach

Transferrin receptor targeting chimeras for membrane protein degradation

Glucose transporters in cancer – from tumor cells to the tumor microenvironment

Harnessing the Lysosomal Sorting Signals of the Cation-Independent Mannose-6-Phosphate Receptor for Targeted Degradation of Membrane Proteins

Lysosome Targeting Chimeras (LYTACs) That Engage a Liver-Specific Asialoglycoprotein Receptor for Targeted Protein Degradation

Photochemically Controlled Release of the Glucose Transporter 1 Inhibitor for Glucose Deprivation Responses and Cancer Suppression Research

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy

Genetically engineered probiotics as catalytic glucose depriver for tumor starvation therapy

Bridging the gap in protein targeting

Novel strategies to improve tumour therapy by targeting the proteins MCT1, MCT4 and LAT1

GLUT1: a Promising Drug Target for Cancer Treatment

Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery

Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies

Intelligent Modular DNA Lysosome-Targeting Chimera Nanodevice for Precision Tumor Therapy

Pickering emulsion templated proteinaceous microparticle as glutathione-responsive carriers for endocytosis in tumor cell

Proteasomal and Lysosomal Degradation for Specific and Durable Suppression of Immunotherapeutic Targets